DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Oncolytics Biotech (ONCY)
Panel-style report (EN/IT): news-first, catalyst timelines, fundamentals/cash runway, pipeline, management/ownership, retail sentiment, risk map, and sources.
Latest key update
Read first
FDA alignment on pivotal Phase 3 design (first-line metastatic pancreatic cancer) — trial launch targeted for H1 2026
Oncolytics reported alignment with the FDA (Type C meeting) on key elements of the Phase 3 pivotal study design for pelareorep in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC), and stated its intent to launch the trial in the first half of 2026.
Finviz chart (click opens Finviz with affiliate parameter).
Quick data panel (verified)
Company focus
Clinical-stage oncology platform centered on pelareorep (dsRNA immunotherapeutic / reovirus isolate).
Cash runway
Company stated cash & cash equivalents of $12.352M (thousands of CAD) as of Sept 30, 2025, and estimated funding into March 2026.
Share count
Management circular shows 107,606,376 common shares issued & outstanding as of Dec 9, 2025 record date.
>10% holders
Management circular states no person/company was known to beneficially own more than 10% of voting rights (as of that document date).
Why ONCY shows up on a catalyst radar
- Regulatory clarity on a pivotal Phase 3 design in first-line mPDAC with a stated launch window (H1 2026).
- Interim-analysis potential mentioned within the proposed pivotal design (timing/rules remain to be disclosed by the company).
- Near-term guided updates for GOBLET (Cohort 5 interim efficacy update including OS component) referenced for Q1 2026.
Analyst snapshot (publicly reported)
H.C. Wainwright reportedly doubled its price target to $10 (from $5) while maintaining a Buy rating (as summarized by market news outlets). Analyst targets can change and are not guarantees.
Timeline (key 2025 milestones)
- Jun 2025 — CEO transition: Jared Kelly appointed CEO.
- Jul 22, 2025 — Company reported it regained Nasdaq minimum bid price compliance (per Q2 2025 report).
- Sept 29, 2025 — Update on planned registration-directed study in first-line PDAC; FDA meeting scheduled for mid-Nov 2025.
- Nov 12, 2025 — Q3 2025 report/MD&A filed (cash runway into March 2026; guidance for Q1 2026 GOBLET update).
- Nov 19, 2025 — FDA alignment on pivotal Phase 3 design for first-line mPDAC; target to launch in H1 2026.
- Dec 9, 2025 — Special meeting rescheduled to Jan 15, 2026 (jurisdiction/domestication-related corporate action).
Forward-looking catalyst timeline (approx. windows)
The items below reflect company-stated windows and expectations (not fixed dates). Timelines can slip.
- Q1 2026 (company-guided) — GOBLET Cohort 5 interim efficacy update, including overall survival component (as referenced by the company).
- Q1 2026 (company-guided) — FDA discussions on plans for a single-arm accelerated-approval study for GOBLET Cohort 4 (as referenced in Q3 forward-looking statements list).
- H1 2026 (company-guided) — Launch activities / trial start for pivotal Phase 3 in first-line mPDAC (FDA-aligned design; company target).
- Jan 15, 2026 — Special meeting date (corporate jurisdiction/domestication vote).
Cash and financing risk (plain reality)
- Cash: $12.352M (thousands of CAD) at Sept 30, 2025; company estimated funding into March 2026.
- Going concern / financing: the company discusses the need for additional financing typical for clinical-stage microcaps.
- Practical takeaway: capital strategy matters alongside clinical timelines, especially into a guided Q1 2026 update window.
Source:
Q3 2025 report (cash/runway)
Management (verified)
- CEO: Jared Kelly (appointed June 2025). Company bio highlights prior biotech legal/strategy experience and involvement in Ambrx and its sale to Johnson & Johnson.
- Executive team (per management circular): CEO Jared Kelly; CFO Kirk Look; CMO Dr. Thomas Heineman; VP Product Development Allison Hagerman; CBO Andrew Aromando.
Ownership (what is clearly stated)
- No >10% holder disclosed to the knowledge of directors/executive officers as of the management circular date.
- Share count reference: 107,606,376 common shares outstanding as of the Dec 9, 2025 record date.
Source:
Management circular
Pipeline and programs (high level)
ONCY is largely a platform story around pelareorep, positioned in GI tumors with multiple cohorts intended to inform a registration path.
- mPDAC: pivotal Phase 3 design aligned with FDA; company stated target to launch in H1 2026.
- GOBLET: company referenced an interim efficacy update for Cohort 5 including an OS component in Q1 2026.
Sources:
FDA alignment PR
|
Q3 2025 report
Sentiment (retail)
This reflects non-professional retail chatter (temperature, not facts). Always verify primary sources.
- Stocktwits: activity tends to spike around FDA-alignment headlines and into trial-update windows.
- Reddit: discussion appears mostly in trading/penny-stock communities when major PR drops.
- X (Twitter): fast amplification; watch for repeated claims without links.
Sources:
Stocktwits stream
|
Example Reddit thread
Risk map (quick)
Catalyst density
Financing overhang
Execution risk
Binary clinical outcomes
Microcap volatility
- Financing: runway into March 2026 creates sensitivity into data windows.
- Clinical binary: readouts can move the tape sharply in either direction.
- Timing: “Q1/H1” windows can slip; delays often reprice expectations.
Source:
Q3 2025 report
Sources (clickable)
- Oncolytics PR: FDA alignment on pivotal Phase 3 design (Nov 19, 2025)
- Q3 2025 report / MD&A (Nov 12, 2025)
- Q2 2025 report / MD&A (includes Nasdaq compliance note)
- PR: registration study update + planned FDA meeting (Sept 29, 2025)
- PR: special meeting rescheduled to Jan 15, 2026 (Dec 9, 2025)
- Investing.com: HC Wainwright PT to $10 (Nov 17, 2025)
- Company bio: Jared Kelly
Disclaimer (educational; no advice)
This report is for informational and educational purposes only and reflects an editorial analysis based on publicly available sources. It is not investment advice, not a solicitation, and not a recommendation to buy or sell any security. Biotech stocks can be extremely volatile; clinical and regulatory outcomes are uncertain; forward-looking statements can change. Always verify primary sources (company filings/press releases) and consider your own risk profile. Past performance is not indicative of future results.
Legal pages: Disclaimer | Terms & Privacy
Legal pages: Disclaimer | Terms & Privacy
My tale (personal view)
The pipeline looks genuinely interesting, but the main obstacle to a “quiet” run-up is the cash situation. In many microcaps, sustained short pressure can force dilutions at unattractive prices, especially as a catalyst approaches. In that setup, management typically faces two paths: (1) aim to deliver strong news at the first meaningful readout and let the stock perform first, then raise at a better price; or (2) secure some capital before the readout, which can crush the current retail base and sometimes sets the stage for a reverse split narrative later. The next key variable is which path management chooses and how it communicates it.
Oncolytics Biotech (ONCY)
Report in formato “a pannelli” (EN/IT): news del giorno in alto, timeline catalyst, fondamentali/cassa, pipeline, management/ownership, sentiment retail, mappa rischi e fonti cliccabili.
News del giorno (chiave)
Prima cosa da leggere
Allineamento con FDA sul design del Phase 3 pivotale (mPDAC first-line) — avvio stimato in H1 2026
Oncolytics ha comunicato l’allineamento con FDA (Type C meeting) sugli elementi chiave del Phase 3 pivotale per pelareorep in prima linea nel carcinoma pancreatico metastatico (mPDAC), indicando l’obiettivo di avviare lo studio nella prima metà del 2026.
Grafico Finviz (click apre Finviz con parametro affiliato).
Pannello dati rapidi (verificato)
Focus società
Biotech clinica in oncologia: piattaforma centrata su pelareorep (immunoterapico dsRNA / isolato di reovirus).
Runway cassa
Nel Q3 la società riporta cassa e equivalenti pari a $12,352 (migliaia di CAD) al 30 set 2025 e stima copertura operativa fino a marzo 2026.
Numero azioni
Nel management circular risultano 107.606.376 azioni ordinarie in circolazione alla record date del 9 dic 2025.
Holder >10%
Nel management circular: per quanto a conoscenza di direttori ed executive, nessun soggetto risulta detenere oltre il 10% dei diritti di voto (alla data del documento).
Perché ONCY entra nel “catalyst radar”
- Chiarezza regolatoria su un Phase 3 pivotale in first-line mPDAC con finestra di avvio dichiarata (H1 2026).
- Potenziale interim analysis citata nel design proposto (tempistiche/regole restano da dettagliare con comunicazioni successive).
- Aggiornamenti vicini su GOBLET (interim efficacy Cohort 5 con componente OS) indicati come attesi in Q1 2026.
Analisti (riportato pubblicamente)
H.C. Wainwright avrebbe raddoppiato il target price a $10 (da $5) mantenendo rating Buy (come riportato da fonti di news finanziarie). I target sono opinioni e possono cambiare; non sono garanzie.
Timeline (milestone 2025)
- Giu 2025 — cambio CEO: Jared Kelly nominato CEO.
- 22 lug 2025 — nel Q2 la società riporta di essere rientrata in compliance Nasdaq (minimum bid).
- 29 set 2025 — update sullo studio registrativo first-line PDAC; meeting FDA previsto a metà novembre 2025.
- 12 nov 2025 — pubblicazione Q3 / MD&A (runway fino a marzo 2026; guidance update Q1 2026 per GOBLET).
- 19 nov 2025 — allineamento FDA su design Phase 3 pivotale mPDAC; obiettivo avvio H1 2026.
- 9 dic 2025 — meeting straordinario riprogrammato al 15 gen 2026 (temi corporate di giurisdizione/domestication).
Timeline catalyst futura (finestre approssimative)
Qui parliamo di finestre indicate dalla società (non date fisse). Le tempistiche possono slittare.
- Q1 2026 (guidance aziendale) — interim efficacy update di GOBLET Cohort 5, inclusa componente overall survival.
- Q1 2026 (guidance aziendale) — confronto con FDA su piani per studio single-arm per accelerated approval su GOBLET Cohort 4 (citato nella lista forward-looking del Q3).
- H1 2026 (guidance aziendale) — avvio/launch del Phase 3 pivotale first-line mPDAC (design allineato con FDA; finestra dichiarata).
- 15 gen 2026 — data meeting straordinario (catalyst corporate).
Cassa e rischio finanziamento (senza giri)
- Cassa: $12,352 (migliaia di CAD) al 30 set 2025; runway stimata fino a marzo 2026.
- Finanziamento: tema centrale tipico delle microcap cliniche; la strategia capitali può pesare quanto i dati clinici nel breve.
- Takeaway: avvicinandosi a un update guidato in Q1 2026, il mercato tende a prezzare anche la probabilità di raccolta fondi.
Management (verificato)
- CEO: Jared Kelly (da giugno 2025). Nella bio aziendale viene evidenziata esperienza corporate/BD e il passaggio in Ambrx con riferimento all’operazione con Johnson & Johnson.
- Executive team (da management circular): CEO Jared Kelly; CFO Kirk Look; CMO Dr. Thomas Heineman; VP Product Development Allison Hagerman; CBO Andrew Aromando.
Ownership (cosa è dichiarato chiaramente)
- Nessun holder >10% noto (per quanto a conoscenza di direttori/executive) alla data del management circular.
- Share count: 107.606.376 azioni in circolazione alla record date 9 dic 2025.
Fonte:
Management circular
Pipeline e programmi (alto livello)
ONCY è soprattutto una platform story su pelareorep, con focus tumori GI e coorti pensate per sostenere un percorso registrativo.
- mPDAC: design Phase 3 pivotale allineato con FDA; avvio dichiarato in H1 2026.
- GOBLET: indicato un interim efficacy update Cohort 5 con componente OS in Q1 2026.
Fonti:
PR allineamento FDA
|
Q3 2025 report
Sentiment (retail)
Commenti di community retail non professioniste: temperatura, non fatti. Verifica sempre le fonti primarie.
- Stocktwits: attività spesso in aumento su headline FDA e in avvicinamento a finestre di update.
- Reddit: discussioni più “headline-driven” su community trading/penny quando escono PR importanti.
- X: amplificazione rapida; attenzione ai claim ripetuti senza link.
Fonti:
Stocktwits stream
|
Esempio thread Reddit
Mappa rischi (quick)
Densità catalyst
Overhang finanziamento
Execution risk
Esiti clinici binari
Volatilità microcap
- Finanziamento: runway fino a marzo 2026 rende il titolo sensibile vicino a finestre dati.
- Binario clinico: i readout possono muovere il prezzo in modo violento in entrambe le direzioni.
- Timing: finestre “Q1/H1” possono slittare e spesso il mercato repricizza su ritardi.
Fonte:
Q3 2025 report
Fonti (cliccabili)
- Oncolytics PR: allineamento FDA Phase 3 (19 nov 2025)
- Q3 2025 report / MD&A (12 nov 2025)
- Q2 2025 report / MD&A (nota compliance Nasdaq)
- PR: update studio registrativo + meeting FDA (29 set 2025)
- PR: meeting straordinario al 15 gen 2026 (9 dic 2025)
- Investing.com: target price HC Wainwright a $10 (17 nov 2025)
- Bio aziendale: Jared Kelly
Disclaimer (solo educational; no consigli)
Questo report è solo informativo/educativo e rappresenta un’analisi editoriale basata su fonti pubbliche. Non è consulenza finanziaria, non è una sollecitazione e non è una raccomandazione di acquisto/vendita. Le biotech possono essere estremamente volatili; gli esiti clinici/regolatori sono incerti; le dichiarazioni forward-looking possono cambiare. Verifica sempre le fonti primarie (filing e comunicati ufficiali) e valuta il tuo profilo di rischio. Le performance passate non garantiscono risultati futuri.
Pagine legali: Disclaimer | Condizioni d’uso & Privacy
Pagine legali: Disclaimer | Condizioni d’uso & Privacy
My tale (opinione personale)
La pipeline è interessante, ma il vero problema per un run-up “tranquillo” è la situazione di cassa. Su molte microcap, gli short premono sull’acceleratore proprio per forzare diluizioni a prezzi ridicoli quando il mercato è più fragile e l’azienda ha bisogno di ossigeno. In questo contesto il management, di solito, ha due strade: (1) puntare a buone notizie al primo readout davvero rilevante e lasciare che il titolo performi, così da poter eventualmente fare un’emissione a un prezzo migliore; oppure (2) assicurarsi un po’ di soldi prima del readout, distruggendo l’attuale base retail e alimentando spesso una narrativa che può portare anche a ragionamenti su reverse split in futuro. La variabile chiave è quale strada sceglieranno e come la comunicheranno.
Biotech Catalyst Calendar
Track upcoming FDA dates and key biotech events here:
https://merlintrader.com/calendario-catalyst/
Scanner for active traders
Try ChartsWatcher free, then unlock 10% OFF with SAVE10
ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.
Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.
Start free – then use SAVE10
No credit card required to start. Apply SAVE10 when upgrading.
Recommended platform
One platform. All your brokers.
Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.
A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.
Get 1 Month Free ➔
Multi-broker workflow + customizable layouts in one platform.
Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site
Find out how I use AI on Merlintrader: AI, retail and Merlintrader
Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.
